Vera Therapeutics, Inc.
VERA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | -$1 | $0 |
| Gross Profit | $0 | $0 | $1 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $126 | $78 | $70 | $22 |
| G&A Expenses | $41 | $24 | $0 | $12 |
| SG&A Expenses | $41 | $24 | $22 | $12 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $167 | $102 | $92 | $34 |
| Operating Income | -$167 | -$102 | -$91 | -$34 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $15 | $6 | $2 | $2 |
| Pre-Tax Income | -$152 | -$96 | -$89 | -$33 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$152 | -$96 | -$89 | -$33 |
| % Margin | – | – | – | – |
| EPS | -2.75 | -2.25 | -3.35 | -2.43 |
| % Growth | -22.2% | 32.8% | -37.9% | – |
| EPS Diluted | -2.75 | -2.25 | -3.35 | -2.43 |
| Weighted Avg Shares Out | 55 | 43 | 27 | 13 |
| Weighted Avg Shares Out Dil | 55 | 43 | 27 | 13 |
| Supplemental Information | – | – | – | – |
| Interest Income | $21 | $8 | $2 | $0 |
| Interest Expense | $8 | $4 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | -$1 | $0 |
| EBITDA | -$144 | -$92 | -$89 | -$32 |
| % Margin | – | – | – | – |